Dana-Farber Cancer Institute: Leukemia, Myeloid trials
The registry lists 16 Leukemia, Myeloid studies with Dana-Farber Cancer Institute as lead sponsor. 2 are open to participants now and 0 have results posted.
Phase 1 8Phase 2 5No phase 3(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- CIML NK Cells With Venetoclax for AMLRecruitingNCT06152809Phase 1
- Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell TransplantationRecruitingNCT06138587Phase 1
- Feasibility Pilot Exploring Variability in Biomarkers and PROs in AMLCompletedNCT04908852
- LY3214996 in Patients With AML Who Are Not Candidates for Standard TherapyCompletedNCT04081259Phase 1
- Prexasertib in Combination With MEC in Relapsed/Refractory AML and High Risk MDS - a Phase I TrialTerminatedNCT03735446Phase 1
- Vaccination With GM-K562 Cells in Patients With Advanced Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) After Allogeneic Hematopoetic Stem Cell TransplantationCompletedNCT00809250Phase 1
- Natural History Study of Patients With Chronic Myelogenous LeukemiaCompletedNCT00429910
- GM-CSF Vaccinations After Allogeneic Blood Stem Cell Transplantation in Patients With Advanced Myeloid MalignanciesCompletedNCT00426205Not applicable
- Vaccine Therapy and Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous LeukemiaCompletedNCT00301093Phase 1
- Multicenter Study of 9-Aminocamptothecin (9-AC) in Patients With Refractory LeukemiaCompletedNCT00251368Phase 1
- Sirolimus With Tacrolimus for Graft-vs-Host Disease Prophylaxis After Related Stem Cell TransplantationCompletedNCT00144703Phase 2
- Sirolimus With Tacrolimus for Graft-vs-Host Disease Prophylaxis After Un-Related Stem Cell TransplantationCompletedNCT00144677Phase 2
- A Study of All-Trans Retinoic Acid (ATRA) and Bryostatin in Patients With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)CompletedNCT00136461Phase 2
- High Dose Ara-C (HDAC) and Interleukin-2 (IL-2) for Patients With Acute Myelogenous Leukemia (AML)CompletedNCT00136448Phase 2
- Study of Vaccination With Autologous Acute Myeloblastic Leukemia Cells in Patients With Advanced Myelodysplasia or Acute Myelogenous LeukemiaCompletedNCT00136422Phase 1
- Study of Iressa in Patients With Relapsed or Refractory Acute Myelogenous LeukemiaCompletedNCT00130702Phase 2